Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HL tablet
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HL tablet is a botanical drug extracted from Magnolia officinalis, developed for the treatment of nonalcoholic fatty liver disease (NAFLD). In clinical studies, it has demonstrated efficacy in reducing hepatic fat content without adversely affecting lipid profiles, body mass index (BMI), or causing significant adverse effects. The mechanism of action is not fully elucidated but is presumed to involve bioactive compounds from Magnolia officinalis that may improve hepatic steatosis and inflammation. The drug was evaluated in randomized controlled trials with both high and low dose regimens over 12 weeks, showing significant reduction in hepatic fat content at higher doses[1][3].
- Brand names
- HL tablet
Beyond the preview
Go deeper on HL tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HL tablet.